Bioventus to Showcase Full Orthobiologics and Ultrasonic Portfolio at NASS in Chicago
Full Launch of BoneScalpel® Access™ at NASS
DURHAM, N.C., Oct. 12, 2022 (GLOBE NEWSWIRE) — Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, will present its spine procedural solutions portfolio at the North American Spine Society (NASS) meeting in Chicago, October 12 through 15.
By combining the power of the neXus® BoneScalpel® for decompression with OSTEOAMP® bone graft for fusions, Bioventus Procedural Solutions is the go-to portfolio for spine surgeons who demand the best. “One year post-acquisition, we are seeing cross-pollination from our combined customer base, ensuring more surgeons have access to these great technologies,” Andrew Hosmer, general manager at Bioventus said. “Legacy neXus users are rapidly adopting OSTEOAMP into their practices and our bone graft customers are expanding their neXus utilization.”
Bioventus continues to invest in the future of both portfolios with the newest product launch, expanding their reach in the rapidly growing minimally invasive spine segment. The BoneScalpel Access handpiece 20 mm blade and Micro Hook Shaver will be available throughout the U.S. on October 17. The BoneScalpel Access handpiece allows surgeons to leverage the many advantages of ultrasonic bone cutting in minimally invasive spinal procedures. Combined with OSTEOAMP Flowable, Bioventus now has a full portfolio for MIS spine procedures, the fastest growing segment of spine surgery.
“BoneScalpel Access is finally allowing ultrasonics to go into spaces and through tubes for spine surgery, allowing me to treat patients optimally with the safest and least invasive way possible. Line of sight down the slightly angled shaft facilitates maximal visualization of the anatomy.” said Tiffany G. Perry, MD, Cedars-Sinai Medical Center.
The Bioventus surgical solutions portfolio brings together innovative products that add value for surgical applications in decompression and fusion.
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for pain treatment, restorative therapies and surgical solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit bioventus.com, and follow the Company on LinkedIn and Twitter. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. BoneScalpel Access is a trademark and SonicOne, SonaStar and neXus are registered trademarks of Misonix, Inc.
Summary for Indications of Use
The BoneScalpel Access handpiece is indicated for use in the fragmentation and aspiration of soft and hard (e.g., bone) tissue in the following surgical specialties: Neurosurgery, Gastrointestinal and Affiliated Organ Surgery, Urological Surgery, Plastic and Reconstructive Surgery, General Surgery, Orthopedic Surgery, Gynecology, External Genitalia – condyloma – benign tumors – (lipomas, fibromas, and leiomyomas) malignant primary metastatic tumors of all types and the following cystic lesions: Bartholin’s cysts, Vestibular adenitis, Inclusion cysts, Sebaceous cysts. Abdominal Area – any abnormal growth, cystic or solid, benign or malignant, involving the ovary, fallopian tube, uterus, or the supporting structures of the uterus except as contraindicated for uterine fibroids. Thoracic Surgery – limited pulmonary reception such as segmetectomies, nonanatomical subsegmetectomies and metastatectomies.
OSTEOAMP may be used in situations where an autograft is appropriate. It should be restricted to homologous use for the repair, replacement or reconstruction of musculoskeletal defects.
SIGNAFUSE Strip is a bone graft substitute intended for use in bony voids or gaps of the skeletal system not intrinsic to the stability of the bony structure. These osseous defects may be surgically created or result from traumatic injury to the bone. SIGNAFUSE Bioactive Bone Graft is indicated to be combined with autologous bone marrow aspirate and packed into osseous defects of the extremities, pelvis and posterolateral spine. When used in the posterolateral spine, SIGNAFUSE Bioactive Bone Graft is to be used as an autograft extender. The device resorbs and is replaced by host bone during the healing process.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, without limitation, statements concerning the benefits of BoneScalpel Access and Bioventus’s plans for commercialization of BoneScalpel Access. In some cases, you can identify forward-looking statements by terminology such as “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. Factors that could cause actual results to differ materially from those contemplated in this press release include, but are not limited to, the adverse impacts on our business as a result of the COVID-19 pandemic; our dependence on a limited number of products; our ability to develop, acquire and commercialize new products, line extensions or expanded indications; our ability to continue to research, develop and manufacture our products if our facilities are damaged or become inoperable; failure to comply with the extensive government regulations related to our products and operations; and the other risks identified in the Risk Factors section of the Company’s public filings with the Securities and Exchange Commission (“SEC”), including Bioventus’s Annual Report on Form 10-K for the period ended December 31, 2021, as updated by Bioventus’s Quarterly Report on Form 10-Q for the period ended July 2, 2022 and as such factors may be updated from time to time in Bioventus’ other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Bioventus’ website at ir.bioventus.com. Except to the extent required by law, the Company undertakes no obligation to update or review any estimate, projection, or forward-looking statement. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business.
Investor and Media Inquiries: